Moderna announces positive phase 3 data for combination vaccine against influenza and covid-19

Mrna-1083 met its primary endpoints, eliciting higher immune responses against influenza virus and sars-cov-2 than licensed flu and covid vaccines in adults 50 years and older, including an enhanced influenza vaccine in adults 65 years and older cambridge, ma / accesswire / june 10, 2024 / moderna, inc. (nasdaq:mrna) today announced that its phase 3 trial of mrna-1083, an investigational combination vaccine against influenza and covid-19, has met its primary endpoints, eliciting a higher immune response than the licensed comparator vaccines used in the trial. "combination vaccines have the potential to reduce the burden of respiratory viruses on health systems and pharmacies, as well as offer people more convenient vaccination options that could improve compliance and provide stronger protection from seasonal illnesses," said stÉphane bancel, chief executive officer of moderna.
MRNA Ratings Summary
MRNA Quant Ranking